Traces the evolution of U.S. regulatory policy with respect to the pharmaceutical industry in the twentieth century. The main theme is the steady move away from the policy of "let the buyer beware" to complex and time-consuming review process, administered by the U.S. Food and Drug Administration, in which both the safety and efficacy of any new drug must be demonstrated prior to the sale in the United States. Basic economics of pharmaceutical business, and reflects, including a tendency to a greater emphasis on marketing and R & D over the centuries. contentious issue of prices for medicines, Patent Policy, and access to experimental drugs at the age of AIDS, are also considered. includes a number statistical charts and graphs of key indicators related to the pharmaceutical industry in the post-World War II era. "Hide
by Willis Emmons, Jeremiah O'Regan, Monica Brand 25 pages. Publication Date: September 10, 1991. Prod. #: 792002-PDF-ENG
Related Case Solutions & Analyses:
Continuing Power of Mass Advertising
Massachusetts Lottery
U.S. Airline Industry–1978-88 (A)
Avon Co.
GlaxoSmithKline in China (A)
PLBsearch: Growing with LinkedIn
Balancing the Power Equation: Suzlon Energy Limited
Amoeba Management: Lessons From Japan’s Kyocera
Global Unichip Corporation A
Cause-Related Marketing: More Buck than Bang?
